CINECA IRIS Institutional Research Information System

To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.

Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry

Gatto, Mariele;ROCCATELLO, Dario;
2015-01-01

Abstract

To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.
2015
33
4
449
456
Adult; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Female; Humans; Immunosuppression; Italy; Lupus Erythematosus, Systemic; Male; Middle Aged; Off-Label Use; Remission Induction; Rituximab; Severity of Illness Index; Treatment Outcome
Iaccarino, Luca; Bartoloni, Elena; Carli, Linda; Ceccarelli, Fulvia; Conti, Fabrizio; De Vita, Salvatore; Ferraccioli, Gianfranco; Galeazzi, Mauro; Ga...espandi
03A-Articolo su Rivista
File in questo prodotto:
File Dimensione Formato  
Roccatello_4_Efficacy and safety.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 602.07 kB
Formato Adobe PDF
  Visualizza/Apri   Richiedi una copia
602.07 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1545603
Citazioni
  • ???jsp.display-item.citation.pmc??? 33
  • Scopus 91
  • ???jsp.display-item.citation.isi??? 81
social impact